CureVac

CureVac Overview

Founded 2000
Founded
Status Private
Employees 500
Employees
Latest Deal Type Grant
Latest Deal Amount $91M
Latest Deal Amount
Investors 17

CureVac General Information

Description

Operator of a fully-integrated biopharmaceutical platform designed to develop mRNA-molecules for therapeutic and prophylactic vaccines. The company's platform uses mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases, enabling physicians to access a large number of different vaccines, including protein and peptide-based vaccines, without toxic effects as well as therapeutics that enhances the immune response of patients

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • Paul-Ehrlich-Str. 15
  • 72076 Tübingen
  • Germany
+49 07071 00000

CureVac Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CureVac Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Grant 16-Mar-2020 $91M 00.000 Completed Generating Revenue
8. Later Stage VC 18-Oct-2017 00000 00.000 Completed Clinical Trials - Phase 2
7. Corporate 08-Nov-2016 000.00 00000 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series F) 03-Nov-2015 00000 00000 00.000 Completed Clinical Trials - Phase 1
5. Corporate 18-Sep-2014 00000 00000 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series D) 18-Sep-2012 00000 00000 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 10-May-2010 000.00 000.00 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series B) 10-Jul-2007 $47.2M $50M Completed Clinical Trials - Phase 1
1. Early Stage VC 01-Jan-2003 $2.77M $2.77M Completed Startup

CureVac Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
ProQinase Formerly PE-Backed Freiburg, Germany 000000&0
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
000000000 Formerly VC-backed Blacksburg, VA 00000 000000&0 00000
0000000 Private Equity-Backed Kulmbach, Germany 00 000000000000
00000000 Formerly VC-backed Mainz, Germany 0000 00.000 00000000 00.000

CureVac Executive Team (19)

Name Title Board Seat Contact Info
Ingmar Hoerr Ph.D Co-Founder, Chairman of the Executive Board & Chief Executive Officer
Pierre Kemula Chief Financial Officer
Franz-Werner Haas Ph.D Chief Operating Officer
Mariola Fotin-Mleczek Ph.D Chief Technology Officer
Bernd Winterhalter Interim Chief Development Officer

8 Former Executives

CureVac Board Members (6)

To view CureVac‘s full board member team, request access >>
Name Representing Role Since
Christof Hettich Ph.D dievini Board Member 000 0000
Friedrich Von Bohlen Ph.D Self Managing Director & Board Member 000 0000
Ingmar Hoerr Ph.D CureVac Co-Founder, Chairman of the Executive Board & Chief Executive Officer 000 0000
Jean Stéphenne CureVac Chairman 000 0000
Mathias Hothum Ph.D dievini Supervisory Board Member 000 0000

CureVac Investors (17)

To view CureVac‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Baden-Württemberg Government 000 0000 000000 0
European Commission Government 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Eli Lilly and Company Foundation Limited Partner Minority 000 0000 000000 0
Landeskreditbank Baden-Württemberg-Förderbank Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial